HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has filed an amendment to its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for its VadovaTM (carbidopa/levodopa) tablets. The Company believes that this amendment addresses the concerns raised in the Agency’s non-approvable letter of March 2006. IMPAX expects to work with the FDA through its evaluation of the amendment, but cannot predict the nature or timing of the FDA’s response.
